Celgene | Bristol Myers Squibb Company

Direct Healthcare Professional Communication

Inrebic®▼ (fedratinib) 100 mg hard capsules: Potential interaction with grapefruit or grapefruit juice

Batch Number M0003AH, Expiry date: Sept 2024

May 2021

Dear Healthcare professional,

Celgene Limited (a Bristol Myers-Squibb [BMS] company) in agreement with the Medicines & Healthcare products Regulatory Agency (MHRA) would like to inform you of the following:

Summary

- **Inrebic®▼ (fedratinib) batch number M0003AH, expiry date: Sept 2024 does not have safety information regarding a potential interaction with grapefruit or grapefruit juice in the Patient Information Leaflet (PIL).**
- **Fedratinib is metabolised by CYP3A4; since grapefruit or grapefruit juice can inhibit CYP3A4 activity, ingestion should be avoided in patients receiving this medicine.**
- **Inform patients that they should not eat grapefruit or drink grapefruit juice during treatment with fedratinib as this may increase the amount of the medicine that passes into their blood.**

Background to the safety concern

Fedratinib is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.

Fedratinib is metabolised by CYP3A4 and concomitant administration with strong CYP3A4 inhibitors increases exposure. During authorisation in Great Britain, the Commission on Human Medicines advised that warnings should be included in the safety information to inform that grapefruit or grapefruit juice should be avoided during treatment.

Celgene Limited
A Bristol-Myers Squibb Company

Celgene Limited
1 Longwalk Road
Stockley Park
UB11 1DB United Kingdom
www.celgene.com

Office +44 (0)208 831 8300
Fax +44 (0)208 831 8301
Medical Information 0800 731 1736
medical.information@bms.com

Registered in England and Wales. Registration Number: 05470441

Following the marketing authorisation approval of fedratinib in Great Britain (GB) on 16 April 2021, the first batch (batch number M0003AH, expiry date: Sept 2024) will be in the European Union (EU) approved packaging. This means that the GB specific safety information regarding a potential interaction with grapefruit or grapefruit juice (*see below for further information*) will not be present in the PIL contained within this specific product pack.

Purpose of this communication
Following consultation with the MHRA, we are informing you of this specific safety information to ensure that this information is communicated to any patients who may be prescribed this batch of fedratinib.

The affected packs of fedratinib can be identified by the **batch number M0003AH, expiry date: Sept 2024.**

PLEASE NOTE: The pharmaceutical composition of this product batch is exactly the same in the EU as in GB; the only difference is the additional PIL safety information in the GB PIL as outlined below, which is not stated in the PIL for this specific product batch:

GB Patient Information Leaflet

Section 2. What you need to know before you take Inrebic
Inrebic with food and drink
You should not eat grapefruit or drink grapefruit juice during your treatment with Inrebic, as they may increase the amount of the medicine that passes into your blood.

The GB Summary of Product Characteristics (SmPC) and the GB PIL containing this important safety information can be accessed from the Electronic Medicines Compendium (emc) at https://www.medicines.org.uk/emc/product/12481/pil.

Please ensure all relevant staff are made aware of the content of this letter and that the information on potential interaction with grapefruit or grapefruit juice is communicated to any patients prescribed fedratinib. Please provide a copy of the GB PIL to patients or provide information on how they can access the GB PIL electronically, if able to do so.

Call for reporting
Inrebic® ▼ (fedratinib) is subject to additional monitoring. This will allow quick identification of new safety information.

Please report ANY suspected adverse drug reactions (ADRs) to the MHRA through the Yellow Card Scheme.

It is easiest and quickest to report ADRs online via the Yellow Card website (www.mhra.gov.uk/yellowcard) or via the Yellow Card app available from the Apple App Store or Google Play Store.

Celgene Limited
A Bristol-Myers Squibb Company

Celgene Limited
1 Longwalk Road
Stockley Park
UB11 1DB United Kingdom
www.celgene.com

Office +44 (0)208 831 8300
Fax +44 (0)208 831 8301
Medical Information 0800 731 1736
medical.information@bms.com

Registered in England and Wales. Registration Number: 05470441

Alternatively, you can report a suspected side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm. You can leave a message outside of these hours.

When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset, treatment dates, and product brand name.

Adverse events should also be reported to Bristol-Myers Squibb Medical Information on 0800 731 1736 or medical.information@bms.com.

Company Contact Point
If you have further questions or require information, please contact Bristol-Myers Squibb Medical Information by phone on 0800 731 1736 or via email medical.information@bms.com.

Yours faithfully,

Dr Hubert Bland
Medical Director, UK & Ireland

Document number: 2010-GB-2100027
Date: May 2021

Celgene Limited
A Bristol-Myers Squibb Company

Celgene Limited
1 Longwalk Road
Stockley Park
UB11 1DB United Kingdom
www.celgene.com

Office +44 (0)208 831 8300
Fax +44 (0)208 831 8301
Medical Information 0800 731 1736
medical.information@bms.com

Registered in England and Wales. Registration Number: 05470441